RP-1843 Arcagen

PROJECT DESCRIPTION

Arcagen – EORTC Research Project 1843 – is a collaborative project with the ERN EURACAN and Roche. It recruited patients with rare cancer, to gain understanding of the molecular landscape of rare cancer. The project recruited around 1000 patients in one of the 10 rare cancer domains as defined by Euracan. A free molecular report (FMI NGS panel) is generated and shared with the clinician, for all eligible patients, within 4 weeks. The project is now in analysis phase. Please visit the Euracan website for more information on Euracan.

Pr. Jean-Yves Blay,
Pr. Jean-Yves Blay,Centre Léon Bérard, Lyon (France)

Molecular analysis (NGS panel) is performed by Foundation Medicine.

For all patients enrolled in the project, a molecular report containing the clinically relevant molecular alterations will be shared with the treating clinician.

Patients with rare cancer, according to the Euracan classification might be eligible in the project.

List of cohort

FFPE material is required to perform the molecular analysis. In case of failure, the analysis could be perform using liquid biopsy.

Arcagen is a collaboration between EORTC and Euracan and is funded by F. Hoffman-La Roche. For more information on the project, please contact the project team 1843@eortc.org.

  • EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers
    (2024 – npj Precision Oncology) Read more
  • Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in Europe
    (2022 – Annals of Oncology) Read more
  • Rare cancers in Europe – rationale for the Arcagen project (pg 43)
    (2021 – Brain Tumour Magazine: World Edition 2021/2022) Read more
  • First results of the EORTC-SPECTA/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN
    (ESMO Open – 2020) Read more

LIST OF COHORTS

For SPECTA, please enroll patients with the tumor type specified in the table, ONLY when the status is green. You can enroll those patients by clicking on the , next to the green status.
Study specific information (HBM, Project Specific selection criteria, CRF completion guidelines…) can be found here . Please note that your electronic database ORTA password is required for access (protocol 1553).

For any questions, please contact the project e-mail address: 1843@eortc.org.

To view the List of Cohorts, please flip your mobile phone horizontally:

Primary disease Status
Cohort 2

  • Patients with advanced or metastatic rare cancer
  • Malignant thymoma; thymic carcinoma; mesothelioma of pleura and pericardium
  • Patients older than 12 years old
 Closed

Primary disease Status
Cohort 3

  • Patients with advanced or metastatic rare cancer
  • Salivary gland tumors of major salivary gland; salivary gland type tumors of head and neck with a strong focus on acinic cell carcinoma; NUT sinus carcinoma
  • Patients older than 12 years old
 Closed

Primary disease Status
Cohort 3

  • Patients with advanced or metastatic rare cancer
  • Pseudomyxoma/adenocarcinoma of the appendix ; cholangiocarcinoma ; gallbladder; germ cell tumors; or neuroendocrine tumors; or small bowel carcinoma
  • Patients older than 12 years old
 Closed

Primary disease Status
Cohort 2

  • Patients with advanced or metastatic rare cancer
  • Sex cord tumours; germ cell tumour; and malignant/immature teratoma;
  • Patients older than 12 years old
 Closed

Primary disease Status
Cohort 2

  • Patients with advanced or metastatic rare cancer
  • Undifferentiated sarcoma of the bone; aggressive angiomyxoma; alveolar soft part sarcoma; small round cell sarcoma without EWSR1 and CIC translocations; undifferentiated pleomorphic sarcoma; undifferentiated sarcoma; myxofibrosarcoma; or sarcoma with an incidence of less than 1 per 10 million
  • Patients older than 12 years old
 Closed

Primary disease Status
Cohort 2

  • Patients with advanced or metastatic rare cancer
  • Rare tumors of the central nervous system
  • Patients older than 12 years old
 Closed

Primary disease Status
Cohort 1

  • Patients with advanced or metastatic rare cancer
  • Rare ovarian cancer; primary peritoneal cancer and/or fallopian-tube cancer, including low grade serous carcinoma, mucinous adenocarcinoma, clear cell adenocarcinoma; sex cord tumors, germ cell tumor; yolk sac tumor, trophoblastic tumor, and malignant/immature teratoma.
  • Patients older than 12 years old
 Closed

Primary disease Status
Cohort 1

  • Patients with advanced or metastatic rare cancer
  • With Adrenocortical carcinoma or Pheochromocytoma
  • Or with Anaplastic Thyroid cancer, Medullary thyroid cancer, or Radioiodine Refractory thyroid cancer
  • Patients older than 12 years old
 Closed

Primary disease Status
Cohort 1

  • Patients with advanced or metastatic rare cancer
  • Mesothelioma of the peritoneum
  • Patients older than 12 years old
 Closed

Primary disease Status
Cohort 1

  • Patients with advanced or metastatic rare cancer
  • Malignant melanoma of the uvea;
  • Patients older than 12 years old
 Closed

Primary disease Status
Cohort 1

  • Patients with advanced or metastatic rare cancer
  • Adnexal carcinoma of the skin, or Merkel cells cancer
  • Patients older than 12 years old
 Closed

Primary disease Status
Cohort 1

  • Patients with advanced or metastatic rare cancer
  • Extra-pulmonary grade 3 Neuroendocrine cancer
  • Patients older than 12 years old
 Closed

Primary disease Status
Cohort 1

  • Patients with advanced or metastatic rare cancer
  • Unknown primary site
  • Patients older than 12 years old
 Closed
BACK TO PROJECTS